{"id":9581,"date":"2026-02-25T17:13:42","date_gmt":"2026-02-25T14:13:42","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9581"},"modified":"2026-02-25T17:13:42","modified_gmt":"2026-02-25T14:13:42","slug":"fda-approval-led-to-more-young-patients-receiving-tavr","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/fda-approval-led-to-more-young-patients-receiving-tavr\/","title":{"rendered":"FDA Approval Led to More Young Patients Receiving TAVR"},"content":{"rendered":"<div>FDA Approval Led to More Young Patients Receiving TAVR<\/div>\n<div><\/div>\n<div>Source<\/div>\n<div>JACC \u2014 February 11, 2026<\/div>\n<div><\/div>\n<div><span> \u2022 In 2019, the FDA approved TAVR for low-risk patients.<\/span><\/div>\n<div><span> \u2022 After this decision, more patients under 65 years began receiving TAVR.<\/span><\/div>\n<div><span> \u2022 Many of these patients were lower risk and might previously have undergone surgery (SAVR).<\/span><\/div>\n<div><span> \u2022 Short-term results were generally good.<\/span><\/div>\n<div><span> \u2022 However, the very youngest patients (&lt;65) showed higher 1-year mortality after adjustment.<\/span><\/div>\n<div><span> \u2022 This may reflect more complex disease patterns or hidden risk factors \u2014 not necessarily a procedural issue.<\/span><\/div>\n<div><span> \u2022 Guidelines still recommend SAVR for patients under 65 years.<\/span><\/div>\n<div><span> \u2022 Careful patient selection and long-term follow-up are essential.<\/span><\/div>\n<div><\/div>\n<div>Key Point:<\/div>\n<div>The 2019 FDA decision shifted practice toward younger, lower-risk TAVR use \u2014 but durability and long-term outcomes remain major considerations.<\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2026.01.011\">https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2026.01.011<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approval Led to More Young Patients Receiving TAVR Source JACC \u2014 February 11, 2026 \u2022 In 2019, the FDA approved TAVR for low-risk patients. \u2022 After this decision, more patients under 65 years began receiving TAVR. \u2022 Many of these patients were lower risk and might previously have undergone surgery (SAVR). \u2022 Short-term results [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9581","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9581"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9581\/revisions"}],"predecessor-version":[{"id":9582,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9581\/revisions\/9582"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}